RT Journal Article
T1 Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT.
A1 Raj, Kavita
A1 Eikema, Dirk-Jan
A1 Sheth, Vipul
A1 Koster, Linda
A1 de Wreede, Liesbeth C
A1 Blaise, Didier
A1 Di Grazia, Carmela
A1 Koc, Yener
A1 Potter, Victoria
A1 Chevallier, Patrice
A1 Lopez-Corral, Lucia
A1 Wu, Depei
A1 Mielke, Stephan
A1 Maertens, Johan
A1 Meijer, Ellen
A1 Huynh, Anne
A1 Passweg, Jakob
A1 Luft, Thomas
A1 Pérez-Simón, Jose Antonio
A1 Ciceri, Fabio
A1 Piekarska, Agnieszka
A1 Hayri Ozsan, G
A1 Kröger, Nicolaus
A1 Robin, Marie
A1 Yakoub-Agha, Ibrahim
AB Myelodysplastic syndromes (MDS) are the second common indication for an Allo-HCT. We compared the outcomes of 1414 matched sibling (MSD) with 415 haplo-identical donors (HD) transplanted with post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis between 2014 and 2017. The median age at transplant with MSD was 58 and 61 years for HD. The median time to neutrophil engraftment was longer for HD being 20 vs 16 days for MSD (p 
YR 2022
FD 2022-09-28
LK http://hdl.handle.net/10668/19519
UL http://hdl.handle.net/10668/19519
LA en
DS RISalud
RD Apr 6, 2025